Clinical Trials Logo

Stroke, Ischemic clinical trials

View clinical trials related to Stroke, Ischemic.

Filter by:

NCT ID: NCT02982278 Completed - Minority Health Clinical Trials

Wide Spectrum Investigation of Stroke Outcome Disparities on Multiple Levels (WISSDOM)

CINGS
Start date: October 2015
Phase: N/A
Study type: Interventional

This research project will evaluate the relationship between cardiovascular risk factors, degrees of physical and mental activity prior to the stroke, brain tissue integrity, post-stroke community participation and neurological recovery after the stroke. Investigators will recruit and study healthy and post stroke participants, gaining insight into the possible mechanisms that explain why the adverse risk profile, which is more commonly present in African-Americans than non-Hispanic Whites in the stroke belt, is translated into a less favorable recovery post stroke.

NCT ID: NCT01937182 Completed - Stroke, Ischemic Clinical Trials

The Efficacy of Citalopram Treatment in Acute Stroke

TALOS
Start date: September 2013
Phase: Phase 2
Study type: Interventional

We wish to conduct a prospective, randomized, double blind, placebo controlled multi center study of the combined neuroprotective and antithrombotic effects of SSRI treatment after stroke. Hypotheses: SSRI treatment commenced in the acute phase of stroke (day 0-7) protects against new thromboembolic events and leads to better rehabilitation. 600 stroke patients will be randomized in a 1:1 ratio. The treatment and follow up period is 6 months. During these 6 months there will be 2 clinical follow up visits, one telephone control and one visit to evaluate compliance regarding medication.

NCT ID: NCT01716481 Recruiting - Stroke, Ischemic Clinical Trials

The STem Cell Application Researches and Trials In NeuroloGy-2 (STARTING-2) Study

STARTING-2
Start date: November 2012
Phase: Phase 3
Study type: Interventional

The objectives of this study was to test hypothesis that ischemic stroke patients having moderate to severe persistent neurologic deficit will have better outcomes with intravenous transplantation of autologous mesenchymal stem cells (MSCs) expanded with autologous serum that is obtained at acute phase of stroke than patients receiving standard treatment.